Lung Cancer Drug Cut Death Risk in Major Study
Patients with specific EGFR mutations saw higher long-term survival rates after surgery when treated with Tagrisso.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you trust that recent medical trial results accurately reflect long-term benefits for cancer patients?
A long-term study presented in 2026 revealed that the drug Tagrisso significantly improved survival for patients with EGFR-mutated non-small cell lung cancer. These results offer new data on outcomes for those who have undergone complete tumor resection.
Why it matters
These findings clarify the potential long-term benefit of adjuvant therapy in preventing recurrence and death for specific lung cancer patients. The results also emphasize the importance of treatment adherence, as stopping the therapy early appears to increase health risks.
In a randomized trial evaluating patients after complete tumor resection, Tagrisso reduced the risk of death by 47% in those with Stage II to IIIA disease. At eight years, 74% of patients treated with the drug remained alive, compared to 58% in the placebo group.
The players
International Association for the Study of Lung Cancer
A global organization that conducts research and shares clinical findings to improve outcomes for lung cancer patients.
The details
The trial evaluated adjuvant Tagrisso in patients with EGFR-mutated non-small cell lung cancer who had previously undergone surgery with curative intent. Final data indicated that discontinuing the medication before the full three-year course doubled the risk of disease recurrence or death. Final safety data were collected during the planned final overall survival analysis.
Timeline
Results were presented at the World Conference on Lung Cancer in 2026.
Estimated survival rates were measured at 8 years post-treatment.
Health Landscape
These results provide an update to the established standards for adjuvant therapy in patients with resected EGFR-mutated lung cancer. The findings highlight how targeted interventions continue to shift long-term survival expectations in this oncological population.
If you are managing EGFR-mutated lung cancer, discuss these survival data and the importance of medication adherence with your oncologist. Always consult your doctor before making any decisions regarding your treatment regimen or the duration of your prescribed therapies.
The takeaway
Adjuvant Tagrisso demonstrated a clear survival benefit in this long-term trial for eligible lung cancer patients. It is vital to discuss your specific treatment timeline and the risks of early discontinuation with your oncology team to ensure the best possible outcomes.
Further reading
For more on evolving research in this field, visit our Cancer section.
Live Poll
Do you trust that recent medical trial results accurately reflect long-term benefits for cancer patients?
